Eisai Co., Ltd. and Biogen Inc. announced new data at the Alzheimer’s Association International Conference 2026 in London, revealing that the LEQEMBI (lecanemab) subcutaneous autoinjector formulation offers efficacy and safety comparable to intravenous administration for early Alzheimer’s disease treatment. The data, presented in the session titled “Lecanemab Subcutaneous Formulation in Early Alzheimer’s Disease: Emerging Clinical Evidence and Practical Use Considerations,” […]